<DOC>
	<DOCNO>NCT02969408</DOCNO>
	<brief_summary>This 12-week , multicenter , open-label study evaluate relationship ABS eMDPI clinical asthma exacerbation ( CAE ) adult patient least 18 year age exacerbation-prone asthma . The ABS eMDPI dose 90 mcg , 1 2 inhalation every 4 hour need , patient dosing limit dose regimen . The purpose study evaluate relationship albuterol dose CAE .</brief_summary>
	<brief_title>A Study Evaluate Relationship Between Use Albuterol Electronic Multidose Dry Powder Inhaler ( eMDPI ) Exacerbations Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>The patient least 1 episode severe CAE past 12 month screen . The patient must able demonstrate appropriate use albuterol ABS eMDPI . The patient use least moderatedose inhaled corticosteroid ( ICS ) ( equivalent fluticasone propionate 440 mcg daily ) additional asthma controller stable dose 3 month prior screen visit . The patient 's baseline asthma therapy regimen , include oral corticosteroid , leukotriene antagonist , 5lipoxygenase inhibitor , longacting beta agonist ( LABA ) , longacting muscarinic agent , cromolyn , biologicals , theophylline , mepolizumab , allow . The patient must willing able comply study requirement specify protocol , include use wearable accelerometer subset patient consent use device . The patient willing discontinue rescue maintenance shortacting beta2 agonist ( SABA antimuscarinic agent replace studyprovided ABS eMDPI duration trial . Women childbearing potential ( surgically sterile â‰¥2 year postmenopausal ) must exclusively samesex partner use highly effective method birth control must agree continue use method duration study 30 day discontinuation investigational medicinal product ( IMP ) . Additional criterion apply , please contact investigator information The patient clinically significant medical condition ( treat untreated ) , opinion investigator , would interfere participation study . The patient confound underlying lung disorder asthma . The patient use investigational drug within 5 halflives discontinue 1 month , whichever longer . The patient pregnant lactate woman , plan become pregnant study . Note : Any woman become pregnant study withdrawn study . The patient know allergic albuterol . The patient history presence `` silent '' infection , include positive test human immunodeficiency virus type 1 2 , hepatitis B , hepatitis C , tuberculosis . Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>